Janssen ’s Phase III trial of rivaroxaban for embolic stroke stopped early

Janssen Research& Development and its development partner Bayer have stopped the Phase III NAVIGATE ESUS clinical trial of Xarelto (rivaroxaban) assessed as a secondary prevention for stroke and systemic embolism in patients who experienced a recent …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news